Analyst consensus rating
Arcus Biosciences Analyst Rating: Strong Buy
Direct answer
Arcus Biosciences's consensus rating is Strong Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $39.91.
Forecast evidence checked October 12, 2026.
Get free Arcus Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $24.47
- Average price target
- $39.91
- High price target
- $47.00
- Low price target
- $23.00
- Low target gap
- -6%
- Target upside
- +63.1%
- High target gap
- +92.1%
- Target range width
- 98.1%
- Consensus rating
- Strong Buy
- Analysts
- 11
- Evidence date
- October 12, 2026
- Valid through
- October 19, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Arcus Biosciences?
Arcus Biosciences has a verified Strong Buy consensus. The same dataset has an average price target of $39.91.
How far are Arcus Biosciences's low and high targets from the recorded price?
The low target implies -6%, while the high target implies +92.1%.
How many analysts are included in Arcus Biosciences's consensus?
The verified consensus includes 11 analysts.
How is Arcus Biosciences's target upside or downside calculated?
The average target of $39.91 is divided by the recorded price of $24.47, then one is subtracted to produce +63.1%. This does not guarantee a future return.
When was Arcus Biosciences's analyst forecast verified?
The data was verified on 2026-10-12. The dataset is valid through 2026-10-19.